Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CAO Sells 2,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the sale, the chief accounting officer directly owned 127,401 shares in the company, valued at $10,199,724.06. This trade represents a 1.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Down 0.2%

BBIO stock traded down $0.13 during midday trading on Monday, hitting $79.96. The company’s stock had a trading volume of 1,335,964 shares, compared to its average volume of 3,035,947. BridgeBio Pharma, Inc. has a 12 month low of $42.09 and a 12 month high of $93.42. The firm has a market capitalization of $15.63 billion, a price-to-earnings ratio of -21.38 and a beta of 0.95. The company has a 50 day moving average of $74.22 and a two-hundred day moving average of $72.80.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. BridgeBio Pharma’s revenue was up 66.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.88) EPS. On average, analysts anticipate that BridgeBio Pharma, Inc. will post -2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on BBIO shares. Morgan Stanley boosted their price target on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. HC Wainwright raised their price objective on BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Truist Financial lifted their target price on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Mizuho decreased their target price on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Finally, Raymond James Financial lowered BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus price target of $95.21.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors have recently modified their holdings of the stock. First Bank & Trust boosted its holdings in shares of BridgeBio Pharma by 1.6% in the 2nd quarter. First Bank & Trust now owns 8,797 shares of the company’s stock worth $655,000 after purchasing an additional 142 shares during the period. GAMMA Investing LLC raised its holdings in BridgeBio Pharma by 13.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,646 shares of the company’s stock valued at $123,000 after buying an additional 199 shares during the period. Commonwealth Equity Services LLC raised its holdings in BridgeBio Pharma by 4.9% during the 4th quarter. Commonwealth Equity Services LLC now owns 5,179 shares of the company’s stock valued at $396,000 after buying an additional 244 shares during the period. Farther Finance Advisors LLC lifted its position in BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its position in BridgeBio Pharma by 0.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,896 shares of the company’s stock worth $3,970,000 after buying an additional 246 shares during the last quarter. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.